Key result
Renal hyperfiltration linked to ~34% greater 3-year MACE risk following AMI.
Why the study?
The clinical implications of renal hyperfiltration remain unclear in patients with acute myocardial infarction.
Does renal hyperfiltration increase the risk of major adverse cardiovascular events in patients with acute myocardial infarction?
Cohort (n=9,561)
Yes
Does renal hyperfiltration increase the risk of major adverse cardiovascular events in patients with acute myocardial infarction?
Renal hyperfiltration is an independent risk factor for major adverse cardiovascular events and mortality in patients with acute myocardial infarction.
Renal hyperfiltration was associated with higher post-MI MACE risk; hypothesis-generating for risk stratification, should not yet change practice.
The potential interaction between the heart and kidneys is thought to contribute to the development of renal hyperfiltration (RHF). However, the clinical implications of RHF remain unclear in patients with acute myocardial infarction (AMI). A total of 9561 AMI patients with estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 were enrolled from a large nationwide cohort. RHF was defined as eGFR > 90th percentile after multiple adjustments. The primary endpoint was a combination of 3 year major adverse cardiovascular events (MACEs) after AMI treatment. The cumulative event rate of MACEs was significantly higher in patients with RHF. In multivariable Cox-regression analysis, RHF increased the 1.34-fold risk of MACE (95% confidence interval [CI] 1.12–1.62) compared to those without RHF. Patients with RHF had a significantly higher risk of all-cause mortality (hazard ratio [HR] 1.64; 95% CI 1.25–2.14) and cardiac death (HR 1.78; 95% CI 1.26–2.51). There was a U-shaped association between the adjusted risk of MACEs and eGFR, with the risk increasing as eGFR exceeded approximately 100 mL/min/1.73 m2. The results demonstrated a consistent pattern in the 1:1 PS-matched population. Our study offers new insights into the risk stratification of AMI patients with RHF.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) conducted a cohort in Acute myocardial infarction (n=9,561). Renal hyperfiltration vs. Without renal hyperfiltration was evaluated on 3-year major adverse cardiovascular events (MACEs) (HR 1.34, 95% CI 1.12-1.62, p=0.002). Renal hyperfiltration increased the risk of 3-year major adverse cardiovascular events by 34% (HR 1.34) compared to patients without renal hyperfiltration following acute myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: